Mylan Fails to Stop Firestorm Over EpiPen Price Increases

August 29, 2016 11:42 PM

17 0

Mylan Fails to Stop Firestorm Over EpiPen Price Increases

Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the sights of Congress this week.

Last week, Chief Executive Officer Heather Bresch was quick to react to the mounting political scrutiny over EpiPen’s price hike with measures to reduce patients’ out-of-pocket costs for the shot’s $600 brand-name version. When that failed to stop criticism, Mylan on Monday announced it would introd...

Also read: KKR buys smart meter financing firm Calvin Capital

Read more

To category page

Loading...